Corvus' soquelitinib shows promise in oncology & autoimmune fields, with Phase 3 PTCL data as a key catalyst. Click here to ...

A high-level overview of Corvus Pharmaceuticals, Inc. (CRVS) stock. View (CRVS) real-time stock price, chart, news, analysis, analyst reviews and more.

Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market uncertainties, we recommend caution. Read more to know why CRVS is a hold.

Tech power players like Semyon Dukach are leading the way in Greater Boston’s venture capital industry. Learn more in our 2025 list of New England's top tech leaders.

The latest price target for Corvus Pharma (NASDAQ:CRVS) was reported by Mizuho on May 20, 2025. The analyst firm set a price target for $11.00 expecting CRVS to rise to within 12 months (a ...

Corvus Pharmaceuticals shares jumped 29% in premarket trading after new interim data in a study evaluating soquelitinib. Shares were trading around $4.33. The stock is down 38% on the year. The ...